

June 15, 2011
AnGes MG, Inc.

GenomIdea, a Subsidiary of AnGes MG, and TSD Japan Sign Contract for
Joint Conduct of Licensing Activities

- Strengthen Licensing Activities toward Global Development of GEN0101/TSD-0014 -

AnGes MG, Inc. is pleased to announce that its subsidiary, GenomIdea, Inc. (hereinafter called “GenomIdea”), has entered into an agreement with TSD Japan, Inc. (hereinafter called “TSD”), for the joint conduct of licensing activities toward promotion of the global development of GEN0101/TSD-0014 (HVJ-E), an anticancer agent under development in Japan.

GenomIdea and TSD signed a license contract dated January 30, 2009 for the development of the novel anticancer agent GEN0101/TSD-0014 (HVJ-E) in Japan for prostate cancer (Refer to the released material dated February 2, 2009: <http://www.anges-mg.com/news/pdf/090202.pdf>). It was deemed necessary to secure new partners to further advance global development, and therefore it was decided that both companies would conduct licensing activities for finding partners.

With the signing of this contract, both companies intend to jointly find pharmaceutical companies as comprehensive partners for global development and marketing of the novel anticancer agent GEN0101/TSD-0014 (HVJ-E) for other cancer areas in addition to prostate cancer.

By signing this contract, GenomIdea will receive profits such as an upfront fee and milestone payments that will be yielded through success in the joint conduct of licensing activities as well as royalties after the launch. Under the terms of this contract, GenomIdea and TSD will allocate these profits at a fixed ratio.

Meanwhile, there will be no effect of this trend on AnGes MG’s business performance during the current fiscal year.